https://commons.ru.ac.za/vital/access/manager/Index ${session.getAttribute("locale")} 5 In vitro diffusion cell design and validation. I. A stability-indicating high-performance liquid chromatographic assay for betamethasone 17-valerate in purified isopropyl myristate receptor phase https://commons.ru.ac.za/vital/access/manager/Repository/vital:6431 Tue 14 May 2024 12:45:06 SAST ]]> Blanching activities of betamethasone 17-valerate formulations: effect of the dosage form on topical drug availability https://commons.ru.ac.za/vital/access/manager/Repository/vital:6432 Tue 14 May 2024 12:44:46 SAST ]]> Topical corticosteroid-induced skin blanching measurement, eye or instrument? https://commons.ru.ac.za/vital/access/manager/Repository/vital:6378 Tue 14 May 2024 12:44:27 SAST ]]> The human skin-blanching assay for comparing topical corticosteroid availability https://commons.ru.ac.za/vital/access/manager/Repository/vital:6433 Tue 14 May 2024 12:44:05 SAST ]]> Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching https://commons.ru.ac.za/vital/access/manager/Repository/vital:6394 Tue 14 May 2024 12:43:42 SAST ]]> In vitro diffusion cell design and validation. II. Temperature, agitation and membrane effects on betamethasone 17-valerate permeation https://commons.ru.ac.za/vital/access/manager/Repository/vital:6422 Tue 14 May 2024 12:42:56 SAST ]]> Ranking of topical corticosteroids: principles and results https://commons.ru.ac.za/vital/access/manager/Repository/vital:6434 Tue 14 May 2024 12:42:12 SAST ]]> The selection and use of natural and synthetic membranes for in vitro diffusion experiments https://commons.ru.ac.za/vital/access/manager/Repository/vital:6379 Tue 14 May 2024 12:41:53 SAST ]]> In vitro release of propranolol hydrochloride from topical vehicles https://commons.ru.ac.za/vital/access/manager/Repository/vital:6435 Tue 14 May 2024 12:41:31 SAST ]]> The effects of elevated and ambient temperature conditions on dilutions of fluocinolone acetonide ointment assessed using the human skin-blanching assay https://commons.ru.ac.za/vital/access/manager/Repository/vital:6380 Tue 14 May 2024 12:41:05 SAST ]]> The human skin-blanching assay for in vitro topical corticosteroid assessment. I. Reproducibility of the assay https://commons.ru.ac.za/vital/access/manager/Repository/vital:6381 Tue 14 May 2024 12:39:53 SAST ]]> The requirements for accurate analysis of pharmaceutical research at South African Universities https://commons.ru.ac.za/vital/access/manager/Repository/vital:6367 Tue 14 May 2024 12:38:47 SAST ]]> New developments in the methodology available for the assessment of topical corticosteroid-induced skin blanching https://commons.ru.ac.za/vital/access/manager/Repository/vital:6384 Tue 14 May 2024 12:37:59 SAST ]]> Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin https://commons.ru.ac.za/vital/access/manager/Repository/vital:6425 Tue 14 May 2024 12:33:53 SAST ]]> Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data https://commons.ru.ac.za/vital/access/manager/Repository/vital:6426 Tue 14 May 2024 12:33:28 SAST ]]> The registration of generic topical corticosteroid formulations in South Africa: a report https://commons.ru.ac.za/vital/access/manager/Repository/vital:6368 Tue 14 May 2024 12:32:59 SAST ]]> Quantification of corticosteroid-induced skin vasoconstriction: visual ranking, chromameter measurement or digital image analysis https://commons.ru.ac.za/vital/access/manager/Repository/vital:6427 Tue 14 May 2024 12:32:38 SAST ]]> Foam drug delivery in dermatology: beyond the scalp https://commons.ru.ac.za/vital/access/manager/Repository/vital:6418 Tue 14 May 2024 12:32:15 SAST ]]> Role of percutaneous penetration enhancers https://commons.ru.ac.za/vital/access/manager/Repository/vital:6446 Tue 14 May 2024 12:13:49 SAST ]]> Analysis of chromameter results obtained from corticosteroid-induced skin blanching. I. Manipulation of data https://commons.ru.ac.za/vital/access/manager/Repository/vital:6424 Tue 14 May 2024 12:12:30 SAST ]]> Relative potencies of topical corticosteroid formulations https://commons.ru.ac.za/vital/access/manager/Repository/vital:6375 Tue 14 May 2024 10:49:55 SAST ]]> Reply to correspondence: P.M. Gaylarde (1986) The human skin blanching assay—use and abuse https://commons.ru.ac.za/vital/access/manager/Repository/vital:6376 Tue 14 May 2024 10:49:17 SAST ]]> A stability-indicating HPLC assay with on-line clean-up for betamethasone 17-valerate in topical dosage forms https://commons.ru.ac.za/vital/access/manager/Repository/vital:6421 Tue 14 May 2024 10:48:59 SAST ]]> Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilizing the human skin-blanching assay https://commons.ru.ac.za/vital/access/manager/Repository/vital:6400 Tue 14 May 2024 10:47:47 SAST ]]> The human skin blanching assay for in vivo topical corticosteroid assessment. II. Subject- and observer-dependent variation in blanching responses https://commons.ru.ac.za/vital/access/manager/Repository/vital:6382 Tue 14 May 2024 10:45:44 SAST ]]> Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing https://commons.ru.ac.za/vital/access/manager/Repository/vital:6356 0.95) was noted for both methods of assessment. The chromameter ED[subscript 50] values determined in this study were approximately 2 hours for both preparations. At this dose duration the instrument would not be sensitive enough to distinguish between weak blanching responses and normal skin for bioequivalence assessment purposes.]]> Tue 14 May 2024 10:45:10 SAST ]]> Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioeqivalence testing [authors' reply in Letters to the Editor] https://commons.ru.ac.za/vital/access/manager/Repository/vital:6423 Tue 14 May 2024 10:44:40 SAST ]]>